KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CRISPR Therapeutics AG (CRSP) Equity Average: 2016-2025

Historic Equity Average for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $1.8 billion.

  • CRISPR Therapeutics AG's Equity Average fell 7.49% to $1.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 billion, marking a year-over-year decrease of 7.49%. This contributed to the annual value of $1.9 billion for FY2024, which is 1.51% up from last year.
  • Per CRISPR Therapeutics AG's latest filing, its Equity Average stood at $1.8 billion for Q3 2025, which was up 2.45% from $1.8 billion recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Equity Average peaked at $2.6 billion during Q3 2021, and registered a low of $1.7 billion during Q1 2021.
  • Over the past 3 years, CRISPR Therapeutics AG's median Equity Average value was $1.9 billion (recorded in 2023), while the average stood at $1.9 billion.
  • Per our database at Business Quant, CRISPR Therapeutics AG's Equity Average soared by 145.40% in 2021 and then dropped by 22.05% in 2022.
  • CRISPR Therapeutics AG's Equity Average (Quarterly) stood at $2.5 billion in 2021, then dropped by 22.05% to $1.9 billion in 2022, then declined by 5.71% to $1.8 billion in 2023, then grew by 7.23% to $1.9 billion in 2024, then dropped by 7.49% to $1.8 billion in 2025.
  • Its Equity Average was $1.8 billion in Q3 2025, compared to $1.8 billion in Q2 2025 and $1.9 billion in Q1 2025.